Nasdaq Drops Accelrys, Affy, Caliper, Luminex from Biotech Index, adds Genomic Health, Solexa | GenomeWeb
This article has been updated from a previous version to clarify the ICB classification system that Nasdaq uses as part of its criteria for including companies in the Biotechnology Index.
 
NEW YORK, May 15 (GenomeWeb News) - A number of genomics firms have been dropped from the Nasdaq Biotechnology index as part of a semi-annual update, the exchange said on Friday.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.